Intervention Review

You have free access to this content

Iron-chelating agents for treating malaria

  1. Helen J Smith1,*,
  2. Martin M Meremikwu2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 16 FEB 2003

DOI: 10.1002/14651858.CD001474

Database Title

Additional Information

How to Cite

Smith HJ, Meremikwu MM. Iron-chelating agents for treating malaria. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD001474. DOI: 10.1002/14651858.CD001474.

Author Information

  1. 1

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, Merseyside, UK

  2. 2

    University of Calabar Teaching Hospital, Department of Paediatrics, Calabar, Cross River State, Nigeria

*Helen J Smith, International Health Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, Merseyside, L3 5QA, UK. cjdhel@liv.ac.uk.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 20 JAN 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (58K)Standard (257K)Full (302K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Desferrioxamine (DFO) vs placebo (plus standard antimalarial regimen): severe malaria, Outcome 1 Death.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Desferrioxamine (DFO) vs placebo (plus standard antimalarial regimen): severe malaria, Outcome 2 Persistent seizures (> 3).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Desferrioxamine (DFO) vs placebo (plus standard antimalarial regimen): severe malaria, Outcome 3 Parasite clearance at day 3.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Desferrioxamine (DFO) vs placebo (plus standard antimalarial regimen): severe malaria, Outcome 4 Phlebitis.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Desferrioxamine (DFO) vs placebo (plus standard antimalarial regimen): severe malaria, Outcome 5 Recurrent hypoglycaemia.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Deferiprone vs placebo: asymptomatic malaria, Outcome 1 Abdominal pain.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Deferiprone vs placebo: asymptomatic malaria, Outcome 2 Headache.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Deferiprone vs placebo: asymptomatic malaria, Outcome 3 Dizziness.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Deferiprone vs placebo: asymptomatic malaria, Outcome 4 Myalgia.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Deferiprone vs placebo: asymptomatic malaria, Outcome 5 Malaise.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Deferiprone vs placebo (plus standard antimalarial regimen): symptomatic malaria, Outcome 1 Death.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Deferiprone vs placebo (plus standard antimalarial regimen): symptomatic malaria, Outcome 2 Coma recovery time.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Deferiprone vs placebo (plus standard antimalarial regimen): symptomatic malaria, Outcome 3 Parasite clearance time.
View Full Article (HTML) Summary (58K)Standard (257K)Full (302K)